Timetable: Type II variation and worksharing application weekly assessment

Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Komboglyze, saxagliptin,metformin hydrochloride, Date of authorisation: 24/11/2011, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Zoledronic Acid Accord, zoledronic acid, Date of authorisation: 16/01/2014, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Xigduo, dapagliflozin,metformin, Date of authorisation: 16/01/2014, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Epidyolex, cannabidiol, Date of authorisation: 19/09/2019, Revision: 18, Status: Authorised

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 May 2025

Human medicines European public assessment report (EPAR): Inhixa, enoxaparin sodium, Date of authorisation: 15/09/2016, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 23, Status: Authorised

European Medicines Agency's data protection notice for selection and recruitment